Turkovac
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Vaccine against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Other names | Erucov-Vac |
| Routes of administration | Intramuscular |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
.svg){kind=small} COVID-19 portal |
Turkovac[2] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
Clinical trials
In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.[3]
In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.[4]
In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey.[5] As of 2023[update] phase III trials continue.[6]
Authorization
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[7] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[8]
References
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
- ^ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac" at ClinicalTrials.gov
- ^ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 " at ClinicalTrials.gov
- ^ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
- ^ "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
- ^ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
- ^ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.
Scholia has a profile for TURKOVAC (Q106532118).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
.png){kind=small} | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=Turkovac&oldid=1247500438"
Hidden categories:
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from November 2023
- Drugs with non-standard legal status
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Articles containing potentially dated statements from 2023
- All articles containing potentially dated statements
- All stub articles